Skip to main content
OpenTrials
Completed

NCT Number: NCT04015934

Predictive Factors of Long Term Outcome in MMN

The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). The aim of this study is to identify prognostic factors of poor outcome.

Data were retrospectively collected from MNN patients in three French centers. Patients were divided into two groups: a good outcome group and a poor outcome group. Demographic, clinical, biological and nerve conduction study features of MMN patients were analyzed. Identification of prognostic factors in MMN could help develop personalized treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

MMN

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Central Hospital

Nancy, 54000, France

About this study

The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). However, 10% of patients progress despite treatment. The aim of this study is to identify prognostic factors of poor outcome.

Data were retrospectively collected from MNN patients in three French centers. Patients were divided into two groups: a good outcome group (patients in remission without IVIg or with spaced IVIg courses), and a poor outcome group (patients dependent on continuous IVIg treatment or deteriorating despite IVIg). Investigators searched predictive factors of long-term outcome in MMN. They studied demographic, clinical, biological and nerve conduction study features of MMN patients.Identification of prognostic factors in MMN could help develop personalized treatment by selecting patients eligible for immunosuppressive drugs before IVIg dependence or progression.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of MNN following the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) Guideline criteria 2010

Exclusion criteria

  • missing data
  • clinical progression features suggested another inflammatory neuropathy,
  • immunosuppressive agents for another pathology.

Treatment and study plan

Primary outcomes

  1. Presence of deteriorating or strongly dependant IVIg NMM

    Time frame: inclusion

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Collaborators

  • Centre Hospitalier Régional Metz-Thionville
  • Hospices Civils de Lyon

Registry information

Official study title

Predictive Factors Identification of Long-term Outcome in Multifocal Motor Neuropathy (MMN) Treated With Intravenous Immunoglobulin (IVIG)

Important dates

Study start
2018
Primary completion
2018
Study completion
2019
First posted
Jul 11, 2019
Registry last updated
Jul 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.